3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
7
Small Cell Lung Carcinoma
6
Fallopian Tube Neoplasms
4
Lung Neoplasms
3
Sarcoma, Ewing
2
Neoplasm Metastasis
2
Ganglioneuroblastoma
2
Uterine Cervical Neoplasms
1
SCLC
1
Rhabdoid Tumor
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Fallopian Tube Mucinous Adenocarcinoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Interventions
Paclitaxel
2
Laparoscopy
2
nilotinib
1
liposomal doxorubicin
1
Topotecan
1
Standard of Care
1
Specimen Handling
1
Practice Guidelines as Topic
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Gemcitabine
1
Electrocardiography
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peritoneal Neoplasms
×
Topotecan
×
30 days
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled